04:27 PM EDT, 10/20/2025 (MT Newswires) -- ZYUS Life Sciences ( ZLSCF ) , a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, just after the close of trade Monday said an independent director has advanced an additional C$0.5 million secured loan to the company.

The loan is in addition to the C$1.5 million loan from the director lender announced by the company on October 17, 2025.

A statement noted the funds will be used for working capital and to advance clinical research, including the company's Phase 2 trial for its Trichomylin softgel capsules.

Monday's statement also noted the loan bears 12% annual interest, matures on October 31, 2027, and can be repaid early without penalty. As part of the deal, the director will receive 724,637 share purchase warrants exercisable at $0.69 for two years, subject to acceleration if certain share price or repayment conditions are met.

Shares of ZYUS Life Sciences ( ZLSCF ) closed up $0.01 to $0.69 on the TSX Venture Exchange.